Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Figure 3 Teneligliptin reduced the expression of the myocardial injury indicators in streptozotocin-induced diabetic mice. A: Creatine kinase-MB level; B: The aspartate transaminase level; C: The lactate dehydrogenase level. ^aP < 0.05 vs control group; ^bP < 0.05 vs streptozotocin group, n = 8. STZ: Streptozotocin; CK-MB: Creatine kinase-MB; AST: Aspartate transaminase; LDH: Lactate dehydrogenase.